Protalix BioTherapeutics (PLX) Misses Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.22 +9.90%
EPS Growth %: +400.0%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +400.0%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $25.77 million versus the consensus estimate of $23.1 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Alamos Gold Inc. (AGI:CN) (AGI) PT Lowered to Cdn$73 at BMO Capital
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
